CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Study of Dovitinib (TKI-258) in Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors With and Without Prior VEGF-Inhibitor Therapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02108782
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:29.848807+00:00
Published At: 2017-07-19T00:00:00+00:00
Record Updated At: 2017-07-19
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Gastrinoma", "Glucagonoma", "Insulinoma", "Pancreatic Polypeptide Tumor", "Recurrent Islet Cell Carcinoma", "Somatostatinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2017-07-19"
protocolSection.identificationModule.nctId: "NCT02108782"
protocolSection.identificationModule.officialTitle: "Phase II Study of Dovitinib (TKI-258) in Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors With and Without Prior VEGF-Inhibitor Therapy"
protocolSection.statusModule.overallStatus: "WITHDRAWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.